Group 1 - The core announcement is that Kelun Pharmaceutical has had five products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 [2] - The announcement was made on the evening of December 8, indicating the company's proactive communication regarding its product portfolio [2] - The inclusion in the drug list is a significant development for the company, potentially enhancing its market access and revenue opportunities [2] Group 2 - The announcement was made by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [2] - The notification regarding the drug list was officially published on December 7, 2025 [2] - This inclusion reflects the government's ongoing efforts to expand access to essential medications for the population [2]

Core Viewpoint - Kolun Pharmaceutical (002422.SZ) announced that five of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) as per the notification from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The inclusion of five products in the National Basic Medical Insurance Drug Catalog is a significant development for the company [1] - This move is expected to enhance the market access and sales potential of the included products [1] - The announcement reflects the company's alignment with national healthcare policies and its commitment to expanding its product offerings in the healthcare sector [1]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. and its subsidiaries have five products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance market expansion and sales scale for the company [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice regarding the inclusion of specific drugs in the 2025 drug list [1] - The inclusion of these products is anticipated to positively impact the company's market network and sales, although the exact effect on operating performance is currently unquantifiable [1] - The 2025 drug list will be officially implemented on January 1, 2026, with further details on reimbursement standards and policies to be announced by relevant government departments [1]

Core Viewpoint - The announcement by Kelun Pharmaceutical indicates that five of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, as released by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - Kelun Pharmaceutical and its subsidiaries have a total of five products included in the 2025 drug catalog [1]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. and its subsidiaries have five products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to enhance market expansion and sales scale for the company [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice regarding the 2025 drug catalog [1] - The inclusion of the company's products in the 2025 drug catalog is anticipated to positively impact the company's market network and sales [1] - The official implementation date for the 2025 drug catalog is set for January 1, 2026, with further details on reimbursement standards to be provided by relevant government departments [1]

Core Viewpoint - Kolun Pharmaceutical has announced that five of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1: Financial Impact - The total sales revenue of the aforementioned drugs for the year 2024 is approximately 51.69 million yuan [1] - For the first half of 2025, the combined sales revenue is expected to be around 309.75 million yuan [1] - These sales figures represent approximately 0.24% and 3.41% of the company's revenue for the respective periods [1]

关于公司药品纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布《关于印发<国 家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品 目录>（2025 年）的通知》（医保发〔2025〕33 号）。根据该通知，四川科伦药 业股份有限公司（以下简称"公司"）及其控股子公司共计 5 个品种纳入《国家 基本医疗保险、生育保险和工伤保险药品目录（2025 年）》（以下简称"《2025 年药品目录》"）。现将相关信息公告如下： 一、产品情况 | （一）本次纳入国家医保目录情况 | | --- | | 药品名称 | 规格 | 适应症 | 协议有效期 | 是否为独 家品种 | | --- | --- | --- | --- | --- | | | 粉体室：按美罗培南 (C17H25N3O5S)计 0.5g; | 适用于成人和儿童由单一或多种对美罗培南敏感的细菌引起的感 染：肺炎（包括院内获得性肺炎）、尿路感染、腹腔内感染、妇科 | | | | 注射用美罗 | 液体室:氯化钠 ...

Core Viewpoint - The strategic partnership between Kolon Pharmaceutical's subsidiary Kolon Biotech and Crescent Biopharma aims to develop and commercialize cancer treatment methods, with potential milestone payments reaching up to $1.25 billion, amidst Kolon Pharmaceutical's declining performance and Kolon Biotech's profitability challenges [1][4]. Group 1: Partnership Details - The collaboration focuses on two early-stage cancer drug candidates: Kolon Biotech's antibody-drug conjugate (ADC) SKB105 and Crescent's PD-1×VEGF dual antibody CR-001, both expected to enter Phase 1/2 clinical trials in Q1 2026 [2][3]. - Kolon Biotech grants Crescent exclusive global development and commercialization rights for SKB105 outside Greater China, while Crescent transfers corresponding rights for CR-001 in Greater China to Kolon Biotech. Both companies plan to explore monotherapy and combination therapy for the drugs [3]. Group 2: Financial Aspects - Kolon Biotech can receive an upfront payment of $80 million and up to $1.25 billion in milestone payments, while Crescent will receive $20 million upfront and $30 million in milestone payments, with both parties entitled to tiered royalties on sales [3]. - Kolon Pharmaceutical's revenue fell by 23.2% year-on-year to 9.083 billion yuan, and net profit decreased by 44.41% to 1.001 billion yuan in the first half of the year, indicating significant pressure on its core business [4]. Group 3: Market Context and Challenges - The collaboration is seen as a potential breakthrough for Kolon Biotech, which reported a loss of 145 million yuan in the first half of 2025, marking a 146.8% year-on-year decline, amid pressures from traditional business and new growth engines [4]. - The development of SKB105 and CR-001 faces significant uncertainties, particularly regarding the inherent risks of drug development and competition from other companies with similar products [5][6]. Group 4: Competitive Landscape - SKB105 targets the relatively niche integrin β6 (ITGB6), with increasing competition in the ADC space, while CR-001 faces a more challenging environment due to the established market presence of competitors like the anti-PD-1 antibody from Kangfang Biologics [6]. - Kolon Biotech must demonstrate superior clinical data or differentiated advantages to successfully promote CR-001 in Greater China, given the competitive landscape [6]. Group 5: Funding and Financial Viability - Kolon Biotech's financial strain is exacerbated by the need for substantial funding for the clinical development, production, and marketing of CR-001, raising concerns about the sustainability of financial support from its parent company, Kolon Pharmaceutical [7].

四川科伦药业股份有限公司（以下简称"公司"）近日获悉，公司控股子公司四川科伦博泰生物医药股份 有限公司（以下简称"科伦博泰"）与Crescent Biopharma, Inc.及其全资子公司Crescent Biopharma Operating Company, LLC (以下合称"Crescent"或"Crescent Biopharma")已建立战略合作伙伴关系，共同开 发和商业化肿瘤治疗手段（包括新型联用疗法）。 一、合作基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002422 证券简称：科伦药业 公告编号：2025-083 四川科伦药业股份有限公司 关于子公司与Crescent Biopharma合作业务进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 CR-001(亦称SKB118) CR-001是一款四价双抗，目前正开发用于治疗实体瘤。其结合了肿瘤学中两种互补且经过验证的作用 机制一一PD-1和VEGF阻断，其中对PD-1检查点的抑制可恢复T细胞识别和摧毁肿瘤细胞的能力，而 VEGF阻断可减少对肿瘤细胞的血液供 ...

Core Viewpoint - The National Medical Products Administration announced that 35 batches of drugs produced by 29 companies do not meet regulatory standards, including two batches of sodium bicarbonate injection from Sichuan Kelun Pharmaceutical Co., Ltd. [1] Group 1: Regulatory Issues - The two batches of sodium bicarbonate injection from Sichuan Kelun Pharmaceutical were found non-compliant regarding pH value, insoluble particles, and visible foreign matter [1][2] - The inspection was conducted by the Anhui Food and Drug Inspection Institute [1][2] Group 2: Company Performance - In the first three quarters of the year, Kelun Pharmaceutical reported total revenue of 13.277 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.201 billion yuan, down 51.41% [3] - The company has experienced a continuous decline in net profit for four consecutive quarters [3][4] - In November, Kelun Pharmaceutical received a registration notice for a short-term financing bond with a registration limit of 4 billion yuan, valid for two years [3] Group 3: Market Data - As of December 4, Kelun Pharmaceutical's stock closed at 34.10 yuan per share, with a total market capitalization of 54.494 billion yuan [3][5] - The stock has seen a price increase of 0.29% on that day [5]